SCHEMBL5125285

SCHEMBL5125285

CCc1cccc(CN(C[C@@H](O)[C@@H](N)Cc2cc(F)cc(F)c2)C(=O)CNC(=O)Nc2ccccc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.37
CTSD P07339 2/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.35
MAOB P27338 1/20 0.35
BACE2 Q9Y5Z0 1/20 0.34
KMT2A Q03164 3/20 0.34
MAPK14 Q16539 1/20 0.34
CTSB P07858 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LAP3 P28838 2/20 0.34
MAPT P10636 2/20 0.34
ANPEP P15144 1/20 0.34
RNPEP Q9H4A4 1/20 0.34
DNPEP Q9ULA0 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14131280 0.84 BACE1 (0.40) BACE1CTSDNPC1RAB9ABACE2
SCHEMBL14131282 0.82 BACE1 (0.38) BACE1CTSDBACE2CTSB
SCHEMBL14131503 0.82 BACE1 (0.43) BACE1CTSDBACE2MAPK14CTSB
SCHEMBL14131371 0.82 BACE1 (0.43) BACE1CTSDBACE2MAPK14CTSB
SCHEMBL14131330 0.81 BACE1 (0.44) BACE1CTSDCYP1A2CYP2C19BACE2
SCHEMBL14131279 0.81 BACE1 (0.39) BACE1CTSDNPC1RAB9ABACE2
SCHEMBL5130327 0.81 BACE1 (0.40) BACE1CTSDPOLBCTSBSMN1; SMN2
SCHEMBL14131502 0.80 ALDH1A1 (0.41) BACE1CTSDPOLBCTSB
SCHEMBL5117473 0.80 SLC2A1 (0.40) BACE1CTSDNPC1BACE2CTSB
SCHEMBL5130825 0.80 BACE1 (0.45) BACE1CTSDNPC1RAB9ABACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 BACE1 1/4885CTSD 100/4885CYP1A2 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.